Esi M Morgan DeWitt

Marc Natter

null null

Peter A Nigrovic

Sarah Ringold

Timothy Beukelman

Yukiko Kimura

Pediatric Rheumatology

English

PubMed

Crossref

POSTER PRESENTATION Open AccessDisease characteristics and medication use in amulticenter cohort of children with juvenileidiopathic arthritis (JIA): preliminary analyses fromthe CARRAnet registrySarah Ringold5*, Timothy Beukelman7, Esi M Morgan DeWitt2, Marc Natter1, Peter A Nigrovic6, Yukiko Kimura3,CARRAnet Investigators4From 2011 Pediatric Rheumatology Symposium sponsored by the American College of RheumatologyMiami, FL, USA. 2-5 June 2011PurposeThe CARRAnet Registry, a multicenter registry of chil-dren with rheumatic diseases in the U.S. organized bythe Childhood Arthritis Rheumatology and ResearchAlliance (CARRA), began enrollment in May 2010. Ouraims were to describe the characteristics of childrenwith JIA enrolled into the registry to date and to identifycharacteristics associated with the use of biologic dis-ease-modifying anti-rheumatic drugs (DMARDs).MethodsData were extracted for all children with JIA who wereenrolled up to December 28, 2010. Children who hadever received biologic DMARDs were compared to chil-dren who had not using relative risks (RR) and unpairedt-tests.Results1072 children with JIA were enrolled during the first 7months by 26 centers. The categorical characteristics ofthe cohort are shown in Table 1 and the continuouscharacteristics of the cohort are shown in Table 2. 77%had received at least one non-biologic DMARD at enroll-ment, most commonly methotrexate. 69% had receivedcorticosteroids during their disease course, most fre-quently intra-articular (49%) and daily oral (36%). 45% ofthe cohort received one or more biologic DMARD duringtheir disease course. The proportion of patients whoreceived specific biologic agents is shown in Table 3.Children receiving biologic DMARDs were older atenrollment (mean age 13 years versus 10 years; p <0.001)and had a longer disease duration (mean 6 years versus 4years; p<0.001). Children with imaging evidence of jointdamage (RR 1.6; 95% CI: 1.3-1.9), positive RF (RR: 1.36;95% CI 1.1 – 1.6), or positive anti-CCP (RR: 1.35; 1.1-1.7)were more likely to have received a biologic DMARD.Children with oligoarthritis were less likely to havereceived a biologic DMARD than other categories.ConclusionThe majority of patients with JIA enrolled into the CAR-RAnet registry has relatively low disease activity, minimaldisability, and have received at least one DMARD. Positiveanti-CCP or RF, joint damage on imaging, older age atenrollment and longer disease duration were associatedwith biologic DMARD use. Limitations include the under-representation of non-English speaking families andenrollment bias. Continued enrollment into this cohortwill support future analyses with increased sample sizesand the potential for longitudinal data analysis.DisclosureSarah Ringold: None; Timothy Beukelman: None; Esi M.Morgan DeWitt: None; Marc Natter: None; Peter A.Nigrovic: None; Yukiko Kimura: None; CARRAnet Inves-tigators: None.5Seattle Children’s Hospital, Seattle, WA, USAFull list of author information is available at the end of the articleRingold et al. Pediatric Rheumatology 2012, 10(Suppl 1):A46http://www.ped-rheum.com/content/10/S1/A46© 2012 Ringold et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative CommonsAttribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction inany medium, provided the original work is properly cited.Author details1Children’s Hospital Boston, Boston, MA, USA. 2Cincinnati Children’sHospital,Cincinnati, OH, USA. 3Hackensack University Medical Center, Hackensack, NJ,USA. 4Stanford, CA, USA. 5Seattle Children’s Hospital, Seattle, WA, USA.6Boston, MA, USA. 7University of Alabama-Birmingham, Birmingham, AL, USA.Published: 13 July 2012doi:10.1186/1546-0096-10-S1-A46Cite this article as: Ringold et al.: Disease characteristics and medicationuse in a multicenter cohort of children with juvenile idiopathic arthritis(JIA): preliminary analyses from the CARRAnet registry. PediatricRheumatology 2012 10(Suppl 1):A46.Submit your next manuscript to BioMed Centraland take full advantage of: • Convenient online submission• Thorough peer review• No space constraints or color figure charges• Immediate publication on acceptance• Inclusion in PubMed, CAS, Scopus and Google Scholar• Research which is freely available for redistributionSubmit your manuscript at www.biomedcentral.com/submitTable 1Characteristuc N (%)JIA CategorySystemic 87 (8)Polyarticular (RF-) 334 (31)Polyarticular (RF+) 266 (25)Extended Oligoarticular 91 (9)Psoriatic 56 (5)Enthesitis-Related 110 (10)Undifferentiated 37 (3)Other or unknown 14 (1)Female 783 (73)RaceWhite 965 (89)Black or African American 62 (6)Asian 29 (3)Other 54 (5)EthnicityHispanic or Latino 101 (9)Positic SerologyANA 483 (45)RF (initial) 88 (8)RF (confirmatory) 46 (4)Anti-CCP 51 (5)HLA-B27 95 (9)UveitisCurrent 46 (4)Past 74 (7)ACR Functional ClassClass I 872 (81)Class II 179 (17)Class III 28 (3)Class IV 4 (<1)Health-related quality of lifeExcellent 242 (23)Very good 437 (41)Good 352 (33)Poor 28 (3)Very Poor 1 (<1)Imaging evidence of joint damageI 265 (25)Table 2Characteristic Mean(Median)RangeAge at enrollment (years) 11 (12) <1 – 22Age at symptom onset (years) 7 (5) <1 – 16Age at first rheumatology visit (years) 7 (7) <1 – 21Disease duration (years) 5 (4) 0 – 18Duration between sympton onset and firstrheumatology visit (years)1 (<1) 0 – 12Number of active joints 2 (0) 0 – 38Table 2 (Continued)Physician global assessment of diseaseactivity2 (1) 0 – 9Parent/patient assessment of disease acticity 2 (1) 0 - 10Parent/patient assessment of overall well-being2 (2) 0 – 9Patrent/patient asessment of pain 3 (2) 0 – 10CHAQ score 0.35 (0.125) 0 – 3Table 3Biologic medication Current use Prior useN (% of biologic users) N (% of biologic users)TNF-alpha inhibitirsAdalimumab 78 (7) 70 (6)Cartolizumab 4 (<1) 0Etanercept 214 (20) 183 (17)Gollimumab 5 (<1) 4 (<1)Inflximab 46 (4) 46 (4)IL-1 InhibitorsAnkira 14 (1) 22 (2)Rilonacept 2 (<1) 2 (<1)Other biologic agentsAbatacept 24 (2) 8 (<1)Rituximab 2 (<1) 8 (<1)Tocilizumab 6 (<1) 0 (<1)Ringold et al. Pediatric Rheumatology 2012, 10(Suppl 1):A46http://www.ped-rheum.com/content/10/S1/A46Page 2 of 2

Disease characteristics and medication use in a multicenter cohort of children with juvenile idiopathic arthritis (JIA): preliminary analyses from the CARRAnet registry

http://dx.doi.org/10.1186/1546-0096-10-S1-A46

Disease characteristics and medication use in a multicenter cohort of children with juvenile idiopathic arthritis (JIA): preliminary analyses from the CARRAnet registry

Abstract

Similar works

Full text

Available Versions

Crossref